SPH4336 Tablets

DRUG3 trials

Sponsors

Shanghai Pharmaceuticals Holding Co., Ltd

Conditions

Advanced Solid TumorsBreast Cancer Brain MetastasesLocally Advanced or Metastatic Breast Cancer

Phase 1

Phase I Clinical Study of SPH4336 Tablets in the Treatment of Advanced Solid Tumors

CompletedNCT05905614

Shanghai Pharmaceuticals Holding Co., LtdAdvanced Solid Tumors

Start: 2020-11-03End: 2023-10-26Updated: 2024-06-17

Phase 2

Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer

RecruitingNCT05860465

Shanghai Pharmaceuticals Holding Co., LtdLocally Advanced or Metastatic Breast Cancer

Start: 2023-09-08End: 2026-12-30Target: 254Updated: 2026-01-14

Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.

RecruitingNCT05872347

Shanghai Pharmaceuticals Holding Co., LtdBreast Cancer Brain Metastases

Start: 2023-09-19End: 2026-12-31Target: 52Updated: 2026-05-05

Related Papers

Efficacy and safety of SPH4336 plus endocrine therapy in HR-positive/HER2-negative metastatic breast cancer with brain metastases: A multicenter, single-arm, phase II study.

Journal of Clinical Oncology2026-05-27

Phase I trial of SPH4336, a novel cyclin-dependent kinase 4/6 inhibitor, in patients with advanced solid tumors

The Oncologist2025-06-01

First-in-human phase 1 study of SPH4336, a novel cyclin-dependent kinase 4/6 inhibitor, in patients with advanced solid tumors.

Journal of Clinical Oncology2024-06-011 citations